Tralokinumab, a “game changer” in the treatment of atopic dermatitis in adolescents


25 October 2021

2 minutes to read

Source / Disclosures

Disclosures: Paller reports having consulted and received honoraria from Leo Pharma.

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

Tralokinumab significantly improved atopic dermatitis in adolescents, according to the results of the phase 3 trial presented at the 2021 fall clinical dermatology conference.

A high affinity human monoclonal antibody that binds and inhibits interleukin-13 (IL-13), tralokinumab has previously shown positive results in adult patients with AD.

“These studies which show the effectiveness of tralokinumab really position interleukin-13 as the key molecule for atopic dermatitis“, Amy S. Paller, doctor of medicine, the chair of the dermatology department of the Feinberg School of Medicine at Northwestern University in Chicago and the study’s international coordinating investigator told Healio. “Atopic dermatitis is such a common disorder in children and adolescents and it’s great to have this option for our adolescent patients. “

Amy S. Paler

The randomized, double-blind, placebo-controlled, parallel-group ECZTRA 6 trial enrolled 301 adolescent patients aged 12 to 17 years.

Patients were randomized to receive 150 mg or 300 mg of tralokinumab or placebo subcutaneously every two weeks for 16 weeks. A loading dose of 300 mg or 600 mg preceded treatment with tralokinumab.

A clinical response, defined as an Investigator’s Overall Assessment Score of 0/1, was observed by 21.4% of people in the tralokinumab 150 mg group (P P = .002). This compared to 4.3% of the placebo group.

A 75% improvement in Eczema Area Severity Index (EASI75) was reported in 28.6% of the 150 mg treatment group (P P = 0.001), compared to 6.4% of the placebo group.

According to a press release from LEO Pharma, secondary endpoints such as an improvement in the severity of AD and an improvement of 4 points or more in the NRS score of weekly mean daily pruritus in adolescents worse and worse. Improvements in quality of life were all achieved in the tralokinumab groups.

If approved by the FDA, tralokinumab will be the second biologic available for the treatment of AD.

“The teens I was able to treat with a biologic for atopic dermatitis have really changed their lives. They developed self-confidence, they were able to participate in sports and social activities that were not possible when their moderate to severe atopic dermatitis controlled their lives, ”said Paller. “He really is a game changer. The teenage years are such an important time for development. … so it’s a critical age to have good treatment options and it’s great to have another biologic.

Leave A Reply

Your email address will not be published.